Tirzepatide is a dual-receptor medication that activates: GLP-1 receptors GIP receptors This dual action improves appetite suppression, insulin sensitivity, and metabolic efficiency
However, LTB4, the main product of 5-LOX, was faster and more potently downregulated in the zileuton group and its level was even less than among healthy animals
Candidates like Eli Lillys retatrutide and Amgens MariTide are raising the bar, with Phase II trials showing weight loss exceeding 24%, a level comparable to that achieved with bariatric surgery
Although the structure of the intestinal microbiota is very complex and the experimental design varies among studies, such as the different timing of HFD induction, distinctions in the duration of metformin treatment, and variations in mouse strains, but the impact of metformin on gut microbiota derived from these studies are nearly consistent
Benefits include reduced side effects, sustainable weight loss, personalized treatment, and improved adherence to the medication regimen
Discussion and Future Directions 7.1